Quabodepistat quabodepistat PHASE3
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaInfectious Disease
Peak Sales Est$300M
Formulations[]
Companies
4578 (ORIGINATOR)100%
Mechanism: DprE1 Inhibitor
Expert: Inhibitor of decaprenylphosphoryl-β-D-ribose 2-epimerase (DprE1), an essential enzyme in mycobacterial arabinogalactan biosynthesis. Disrupts cell wall integrity of Mycobacterium tuberculosis, including MDR and XDR strains.
Everyday: Blocks an enzyme that TB bacteria need to build their protective cell wall. Without this wall, the bacteria become vulnerable and die — even drug-resistant strains that have learned to dodge other antibiotics.
Targets: []
Programs (1)
IndicationStageKey StudyRegional Status
TB drug-susceptiblePHASE3NCT07209761[]
Notes
Novel TB drug targeting DprE1 enzyme. Gates Foundation grant-funded. NCT07209761.
Data from Supabase · Updated 2026-03-24